Dry Eye Clinical Trial
Official title:
Crosslinked Hyaluronic Acid With Liposomes and Crocin in the Treatment of Dry Eye Disease Due to Moderate Meibomian Glands Dysfunction
A total of 50 eyes were analyzed (25 patients). The subjects selected were over 18 years of age. No gender distinction was made in the choice of subjects. All subjects were carriers of silicone hydrogel contact lenses. The antecedents of the eye diseases not identified, neither the previous eye surgeries nor the systemic or ocular medication. All patients read, understood and signed an informed consent form of the study.
A study was performed using the contralateral eye, the study groups were randomized. The
choice of eye for each tear was random and established as an artificial tear A and artificial
tear B. The patients were not previously warned about the type of artificial tear they were
going to use or the difference that existed between them, therefore, they were unaware of the
benefits that such tears could offer them. The examiner did know what tear was applied to
each eye.
As for the lubricants used; Tear A (Aquoral Forte®, ESTEVE®, Farmigea, Pisa, Italy) was a
combination of 0.4% unridged hyaluronic acid and 0.2% Galacto-xyloglucan. The
galacto-xyloglucan is extracted from the tamarind seed. It consists of 30 single doses, each
with 0.5 ml and have a daily use closure, that is, it can not be used once 12 hours have
passed since the dose was opened. This lubricant lacks preservatives.
On the other hand, tear B (Aquoral Lipo® [Spain] / Lumixa® [Italy], ESTEVE®, Farmigea, Pisa,
Italy) is a combination of three components; cross-linked hyaluronic acid (CXL) at 0.15%,
crocin and liposomes. It is an ophthalmic lubricant and antioxidant solution. Its package is
10 ml multidose, so it can be used for a long time. It is composed of liposomes, sodium salt
of crosslinked hyaluronic acid 0.15%, ethylenediaminetetraacetic acid (EDTA) disodium salt
and crocin. Although this tear comes in a multi-dose container, it does not contain a
preservative due to the dispenser that does not let microorganisms from outside. Contact
lenses can be used while both lubricants are applied. In this regard, the study patients used
their silicone hydrogel contact lenses monthly during the study.
All patients in the study had a period of one month without using any type of artificial tear
or eye drops. Once this time or study was over, the patients were explained how artificial
tears should be instilled. The visits were carried out blindly by research optometrists. Who
did not know how the distribution of artificial tears in patients had been. The artificial
tears were administered 3 times a day for 6 weeks and the subjects belonging to the study
underwent a clinical examination in the period prior to treatment and 45 days after the
treatment, once the treatment with artificial tears. He was repeated the tests of the
beginning, nevertheless, the meibografía was not realized, since the use of artificial tears
was not going to cause the growth of the glands of Meibomio
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |